[Edaily Reporter Park Jeong-soo] #Prestige Biologics announced on the 10th that it has signed a contract for the contract manufacturing of active pharmaceutical ingredients (APIs) worth 2.66643 billion won. The contract amount represents 21.27% of last year’s revenue, and the contract period runs until March 31 of next year. The identity of the contracting party was not disclosed at the request of the other party to maintain confidentiality. The confidentiality period extends until the end of March next year.
Disclosure Plus
Prestige Biologics Signs 2.7 Billion Won Contract for Contract Manufacturing of Active Pharmaceutical Ingredients
Park Jung-Soo
2026-06-10 15:20:40
Economy
Corporation
IT·Science
Economy
NEXTBIOMEDICAL CO., LTD., Which Made Its Mark Globally with NexPowder, Named a “KOSDAQ Rising Star” for the Second Consecutive Year
#NEXTBIOMEDICAL CO., LTD., a company specializing in innovative medical devices, has been named to the Korea Exchange’s “KOSDAQ Rising Star” list for the second consecutive year, once again demonstrat…
Corporation
Celltrion, Buoyed by Direct Sales, Expands into Asia’s Pharm-Emerging Markets... Solidifies No. 1 Position and Prepares New Drugs
Celltrion(068270)Celltrion is strengthening its market dominance in Asia—a leading “Shinhung” (emerging pharmaceutical) market—by leveraging its unrivaled direct-to-market competitiveness. While its f…
IT·Science
LGCHEM,LTD Begins Preclinical Trials for ‘GNV205,’ an Immunotherapy Drug Based on Genube Technology
#
LGCHEM,LTD is set to begin preclinical research on “GNV205,” an antibody-cytokine fusion candidate acquired from the domestic biotech firm GenuV. The company plans to develop it as a next-gen…
